Solvay Pharmaceuticals today announces the signing of an agreement with Bioprojet that extends its gastro-enterology portfolio with racecadotril, a treatment for acute diarrhoea.

Solvay Pharmaceuticals has registration agreements and exclusive distribution rights for Russia and CIS, several countries in Central and Eastern Europe and for Canada, South-Africa and India, as well as for other countries in Europe and Asia.

 

This geographical extension to Solvay’s existing GI portfolio provides doctors and their patients with a new product, with a highly specific intestinal anti-secretory activity, suitable for the treatment of acute diarrhoea in babies, children and adults.

 

Diarrhoea represents an important pathology (still life-threatening in several geographical areas, particularly in children) and racecadotril is a treatment, which acts specifically on the secretory function of the intestine, without affecting its motility, which offers a safe and useful alternative to doctors.  In general symptomatic therapy of acute diarrhoea can help children and adults to return to normal daily activities more quickly and improve their quality of life.

 

Solvay Pharmaceuticals has more than fortyyears’ experience in gastro-enterology and is committed to this community, providing therapies that can help with product like CREON®, DUPHALAC®, DICITEL® and DUSPATAL

 

Solvay Pharmaceuticals is a research driven group of companies that constitute the global pharmaceutical business of the Solvay Group.  The company seeks to fulfill carefully selected, unmet medical needs in the therapeutic areas of neuroscience, cardio-metabolic, influenza vaccines, gastroenterology, specialized markets and men’s and women’s health. Its 2005 sales were EUR 2.3 billion and it employs approximately 10000 people worldwide. For more information, visit solvaypharmaceuticals.com.

 

SOLVAY is an international chemical and pharmaceutical Group with headquarters in Brussels. It employs some 30000 people in 50 countries.  In 2005 its consolidated sales amounted to EUR 8.6 billion generated by its three activity sectors: Chemicals, Plastics and Pharmaceuticals. SOLVAY (Euronext : SOLB.BE – Bloomberg: SOLB.BB – Reuters: SOLBt.BR) is listed on the Euronext stock exchange in Brussels. Details are available at www.solvay.com.

 

For further information please contact :

Roger Bickerstaffe , VP Global Communications
Solvay Pharmaceuticals
Tel: +31 (0) 294 477 242
Fax: +31 (0) 294 477 112
E-mail : roger.bickerstaffe@solvay.com

 

Robert van Bijlert, Communicator
Solvay Pharmaceuticals
Tel: +31 (0) 294 479 577
Fax: +31 (0) 294 477 112
E-mail: Robert.vanbijlert@solvay.com